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medications and raloxifene in the treatment of osteo-
porosis. METHODS: Data from a large health insurer
were used to identify 59,902 osteoporosis patients who
initiated drug therapy between January 1, 1998 and
August 30, 2000. Multivariate statistical models were
developed for duration of therapy, uninterrupted therapy
over one year, time to discontinuation, time to a change
in therapy and health care costs over one year. Separate
models were estimated for the effect of drug use patterns
(compliance, switching) and initial drug therapy (ralox-
ifene, bisphosphonates vs. HRT). Other independent
variables included age, gender, type of insurance, history
of fractures, and patient diagnostic and drug proﬁles at
baseline. Sensitivity analyses were conducted to investi-
gate if the impact of alternative drugs varied with age.
RESULTS: Bisphosphonate patients were more compliant
than HRT patients, though compliance rates were below
25% for all drugs. Drug use patterns for raloxifene
patients did not differ signiﬁcantly from HRT patients.
Compliance was correlated with a reduced risk of hip
fractures of 43% (p < 0.05) and lower health care costs
of -$213 (p < 0.01), while switching increased the risk of
hip fractures by 84% (p < 0.05) and increased costs by
$278 (p < 0.01). Bisphosphonate patients were twice as
likely as HRT patients to experience vertebral, Colles and
other fractures and experienced higher health care costs
relative to HRT patients of $510 (p < 0.0001). The 
estimated impacts of raloxifene and bisphosphonates
improve signiﬁcantly with patient age. For example,
raloxifene’s impact on total costs improved from +$314
for patients under 55 to -$570 for patients over 65.
CONCLUSIONS: Compliance with drug therapies for
osteoporosis over a 1-year period is poor (<25%) leaving
patients at risk for fractures and higher health care costs.
Alternatives to HRT were associated with better patient
outcomes, especially for older patients.
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OBJECTIVE: To determine if clinical outcomes and total
medical and drug costs are affected by noncompliance
with alendronate. METHODS: Data was gathered retro-
spectively from an integrated pharmacy and medical
claims database. Patients over the age of 18 years old who
were taking alendronate daily at the beginning of the
accrual period were selected for inclusion. Patients with
a diagnosis of Paget’s disease, renal disease/failure were
excluded. Demographics including mean age, sex, and
concomitant medications and diagnoses were collected.
Medication adherence was calculated by dividing the sum
of days of supply dispensed by the sum of days in all reﬁll
intervals. Percent compliance was broken down into
quintiles and cohort groups. Days on therapy, number
and type of disease sequela, time to ﬁrst disease sequela
event, monthly cost of disease sequela and adverse drug
events, and monthly total medical and drug costs were
calculated for each group. ANOVA or non-parametric
equivalents were used. RESULTS: 13,275 patients (93%
females) were included in this analysis. The mean age 
was 67.3 years and the average number of diagnoses per
patient was 7.9. Ninety-four percent of the study popu-
lation had a diagnosis of osteoporosis. Sixty-six percent
of the patients were >80% compliant. Total costs for the
compliance cohorts were analyzed using the Kruskal-
Wallis test for non-parametric data, and were signiﬁcantly
higher in the =>80% versus the <80% compliant cohort
($725.46 vs $547.03, p < 0.0001). Patients in the =>80%
cohort experienced more disease sequelae, and the
medical costs associated with them were lower but were
not statistically signiﬁcant (p = 0.09). CONCLUSION:
Compliance with alendronate therapy did not positively
affect outcomes with respect to number of disease seque-
lae or their costs. Since bone loss is cumulative, and 
bisphosphonates have been proven to reduce and prevent
fractures, cost savings due to adherence may be realized
at points beyond the initial year of treatment.
ARTHRITIS/OSTEOPOROSIS—Quality of
Life/Preference Based Outcomes
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WTP estimates are highly tangible and thus suitable 
for measuring health care preferences. The feasibility 
and usefulness of WTP in JIA has not been examined.
OBJECITVE: To assess the feasibility and construct valid-
ity of the WTP for measuring health preferences in JIA.
METHOD: Parents were asked to estimate the monthly
US dollar amount they would be willing to pay to obtain
for their child 1) Drug A that provides near complete
relief of arthritis symptoms (WTP(A)); and 2) Drug B that
eliminates gastrointestinal (GI) symptoms (WTP(B)). A
closed-ended question approach (yes/no) was used 
with random assignment of the initial bids (Drug A:
$50/$125/$200/$300; Drug B: $5/$25/$30/$40). Parents
who agreed to pay the initial bid were then asked whether
they would pay 200% and then 400% of this initial 
bid. Information was obtained regarding family income,
healthcare expenses as well as on various JIA outcomes:
number of involved joints; visual analog scales of pain,
GI discomfort and overall well-being; Childhood Health
Assessment Questionnaire (CHAQ); the Pediatric Quality
